Satsuma Pharmaceuticals (NASDAQ: STSA) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Satsuma provided the long-awaited update on their STS101 development plans following the disappointing Phase 3 data from the EMERGE trial last fall. Based on a detailed review of the EMERGE data, the company has identified multiple factors that may have played a role in trial’s failure. We maintain our Neutral rating as we review these findings in more detail, and assess the likelihood of STS101 succeeding in its next Phase 3 trial. However, we are encouraged by our initial review of the information disclosed, as well as the support private investors, who have had more time to review and digest the data, have shown by investing an additional $80M in the story.”
To request access to the full report, visit https://ibn.fm/VNdLG
About Satsuma Pharmaceuticals, Inc.
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product candidate for the acute treatment of migraine. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be quickly and easily self-administered with a proprietary pre-filled, single-use, nasal delivery device. DHE products have long been recommended as a first-line therapeutic option for the acute treatment of migraine and have significant advantages over other therapeutics for many patients. However, broad use has been limited by invasive and burdensome administration and/or sub-optimal clinical performance of available injectable and liquid nasal spray products. STS101 is specifically designed to deliver the clinical advantages of DHE while overcoming these shortcomings. Satsuma is headquartered in South San Francisco, California with operations in both California and Research Triangle Park, North Carolina. For further information, please visit www.satsumarx.com.
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.